SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a notable price decline, prompting widespread community debate on whether it signifies a buying opportunity or further downside, particularly amidst trending rumors associating its origins with Jeffrey Epstein.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending after an earnings miss and weak guidance, compounded by a leadership change, triggering a steep sell-off as the community sharply divides between those labeling it 'PainPal' on a path to further declines and others viewing it as an 'oversold' deep value opportunity given its low valuation and share repurchase program.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as Bitcoin's significant price drop pushes the company's vast BTC holdings underwater, fueling intense community debate about the viability of its leveraged Bitcoin strategy, potential dilution, and the financial implications leading up to its earnings report. Investors are sharply divided between those fearing a "death spiral" and others viewing current levels as a "buy the dip" opportunity for a Bitcoin proxy.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the US House passing a government funding bill prompts debate about a potential "V-shaped" market recovery, though many traders remain cautious, fearing a "bull trap" amidst broader concerns over an "AI bubble" and shifts in tech leadership. The community is actively discussing whether a sustained rebound or further "bloodbath" in tech is imminent, with upcoming AMD earnings also a key focus.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir (PLTR) is surging after reporting "blowout" Q4 earnings and strong 2026 guidance, driven by accelerating U.S. commercial demand and AI adoption. Community discussion highlights both sustained growth potential and concerns over its still-high valuation, especially as it shows relative strength during a generally weak market.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk shares plunged following cautious 2026 guidance that forecasts a sales and operating profit decline amid U.S. pricing pressure and patent expirations, prompting a simultaneous share repurchase announcement. Despite the negative outlook, the community largely views the sell-off as an overreaction, pointing to surprisingly strong early uptake of the oral Wegovy pill and positive CagriSema trial results as key long-term growth drivers against rising competition.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending amidst a significant stock price decline, which the community largely attributes to aggressive short selling and a broader market rotation out of small-cap AI names. Despite this, many investors are actively dollar-cost averaging and holding, citing strong fundamentals, recent partnerships, and anticipating a major rebound, while others express frustration and question the company's long-term viability.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as its stock experiences significant price volatility, with many in the community attributing recent drops to perceived market manipulation and short-seller pressure. This occurs despite bullish updates from a recent webinar detailing a substantial AI data center pipeline and backlog, coupled with an analyst price target upgrade, fueling a debate between strong fundamentals and persistent market action.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is a major talking point amid a significant stock price decline ahead of its earnings report, fueling community debate over CEO leadership and perceived undervaluation, while proposed global age restrictions on social media and the company's AR glasses spin-off add to the trending conversation.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing a broad market sell-off, driven by escalating geopolitical tensions following a US military action involving an Iranian drone, alongside ongoing concerns about an AI sector valuation correction and a significant crypto market downturn, leading to community discussions of a 'bloodbath' and hopes for a 'V-shaped recovery' at crucial support levels.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biomea Fusion, Inc. (NASDAQ:BMEA) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten ratings firms that are presently covering the stock, MarketBeat...

Biomea Fusion Spotlights Diabetes, Obesity Pipeline at JPMorgan Conference, Sets 2026 Milestones

Biomea Fusion (NASDAQ:BMEA) highlighted two clinical-stage programs focused on diabetes and obesity during a presentation at the 44th Annual JPMorgan Healthcare Conference, with CEO Mick Hitchcock...

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the firm, MarketBeat Ratings...

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, Marketbeat Ratings...

Biomea Fusion (NASDAQ:BMEA) Price Target Cut to $6.00 by Analysts at Citigroup

Citigroup reduced their price objective on Biomea Fusion from $7.00 to $6.00 and set a "buy" rating on the stock in a research report on Monday...

Biomea Fusion FY2025 EPS Estimate Lowered by HC Wainwright

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - HC Wainwright lowered their FY2025 EPS estimates for Biomea Fusion in a research note issued on Wednesday, November 5th. HC Wainwright analyst J...

Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Moderate Buy" by Analysts

Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine brokerages that are covering the stock, MarketBeat.com reports. One...

Biomea Fusion (NASDAQ:BMEA) Given New $12.00 Price Target at D. Boral Capital

D. Boral Capital dropped their price target on shares of Biomea Fusion from $16.00 to $12.00 and set a "buy" rating on the stock in a research note on Wednesday...

Shares of Biomea Fusion drew heightened attention from retail investors on Tuesday after the company disclosed a public offering of its common stock and warrants.&nbsp;The stock closed up 10.3% at $2.9 on Tuesday but dropped 24.8% to $2.18 in after-hours trading.The offer includes shares, pre-funded warrants in place of shares to certain investors and accompanying warrants for the purchase of shares.Biomea said it will also give the underwriters a 30-day option to buy up to 15% more shares and pre-funded warrants. Jefferies is the sole book running manager.The offering is being made under a shelf registration and is expected to close on or around June 20, subject to customary closing conditions.&nbsp;Biomea said the completion, size, and terms of the offering are subject to market conditions and are not guaranteed.The offering comes just days after Biomea Fusion reported updated data from its Phase I Covalent 103 trial of BMF-500 in relapsed or refractory acute leukemia.&nbsp;The study, presented at the European Hematology Association Congress, showed early signs of clinical benefit in heavily pretreated patients with FLT3 mutations.&nbsp;The company said it plans to conclude internal development of BMF-500 in oncology and is exploring strategic partnerships to advance the program.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.One user said the raise could bring in around $30 million and&nbsp;added that while the added dilution might pressure the stock short-term, the reduced risk could unlock further upside, predicting a return above $3 in the coming weeks.&nbsp;<stembedurl>https://stocktwits.com/hashbridges/message/618219066</stembedurl>Another user expressed disappointment at the timing of the offering, saying they anticipated it at a higher price and would now hold the stock through year-end.<stembedurl>https://stocktwits.com/aquira/message/618214880</stembedurl>The stock has declined 21.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Portrait of a doctor woman on the background of stock charts. | Image source: Getty Images

Biomea Fusion Slides After-Hours Following Stock-And-Warrant Offering; Retail Traders See Rebound Ahead

The offering follows early clinical data from Biomea’s BMF-500 leukemia program, which showed encouraging responses in heavily pretreated patients. 

Equity

Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know

This account has been verified as an official BMEA representative.

Verified Account

Biomea Fusion IR

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.

Biomea Fusion Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $UBER earnings on Wednesday?

Current Price	$1.08
Prev Close	$1.10
Open	$1.12
Dividend Yield	0.00%
50-Day Moving Average	$1.27
Beta	1.46
Avg. Volume	1.3M
PE Ratio	-0.46

52-Week High	$4.23
52-Week Low	$0.8719
Market Capitalization	$77.77M
EPS (Annual)	-$3.83
Price to Book	4.19
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

BMEA
Biomea Fusion Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BMEA News

BMEABiomea Fusion Inc